CTCs May Predict Breast Cancer Recurrence.
Findings from a prospective study indicate that for patients diagnosed with ER-positive, HER2-negative breast cancer, the presence of circulating tumor cells several years afterward considerably ups the risk-by nearly 22-fold-of their disease making a late reappearance.